← Leaderboards
Yan Xu
Cleveland Clinic Foundation
$4,438,394
Attributed
$5,452,138
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $644.7K · FY2005–15$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$5,452,138 · 5
By mechanism
R01$4,891,338 · 3
R21$560,800 · 2
Top collaborators
- Li Zhang5 shared
Most similar at Cleveland Clinic Foundation
Same institution · by research overlap
- Bryan R. G. Williams$8,873,982
Others in their field
Top investigators on “Mitogen Activated Protein Kinase”
- John Blenis · Harvard University (Medical School)$21,988,009
- Anton M Bennett · Yale University$16,786,771
- Melanie H Cobb · University Of Texas Sw Med Ctr/Dallas$16,542,922
- Channing J Der · University Of North Carolina Chapel Hill$11,867,290
- Richard F Loeser · Rush University Medical Center$11,754,867
- Bradford C Berk · University Of Rochester$11,712,110
Research focus
Mitogen Activated Protein KinaseNeoplastic CellLysophospholipidsMalignant NeoplasmsSignal TransductionBaseCessation Of LifeCancer EtiologyUnited StatesMolecularCell PhysiologySphingosineReportingAffectCell LineTumorNeoplasm MetastasisEarly DiagnosisCell Growth RegulationMediatingCancer CellCellsG ProteinAdoptive Transfer
Grant awards (20)
Role of immune cell OGR1 in prostate cancer development and the mechanisms involv$405,077
R01 · FY2015 · CA · contact PI
Role of immune cell OGR1 in prostate cancer development and the mechanisms involv$398,767
R01 · FY2014 · CA · contact PI
Role of immune cell OGR1 in prostate cancer development and the mechanisms involv$384,136
R01 · FY2013 · CA · contact PI
Role of immune cell OGR1 in prostate cancer development and the mechanisms involv$420,784
R01 · FY2012 · CA · contact PI
Role of immune cell OGR1 in prostate cancer development and the mechanisms involv$418,724
R01 · FY2011 · CA · contact PI
Critical evaluation of LPCs markers for colorectal cancer$169,400
R21 · FY2010 · CA · contact PI
Critical evaluation of LPCs markers for colorectal cancer$169,400
R21 · FY2009 · CA · contact PI
Novel Lipid Signaling Pathways in Ovarian Cancer Cells$319,620
R01 · FY2007 · CA · contact PI
Novel Lipid Signaling Pathways in Ovarian Cancer Cells$325,829
R01 · FY2006 · CA · contact PI
Novel Lipid Signaling Pathways in Ovarian Cancer Cells$337,088
R01 · FY2005 · CA
Novel Bioactive Lipid Receptors in Growth Regulation$212,100
R01 · FY2005 · CA
Novel Bioactive Lipid Receptors in Growth Regulation$92,183
R01 · FY2005 · CA
Novel Lipid Signaling Pathways in Ovarian Cancer Cells$3,337
R01 · FY2005 · CA
Novel Lipid Signaling Pathways in Ovarian Cancer Cells$340,425
R01 · FY2004 · CA
Novel Bioactive Lipid Receptors in Growth Regulation$306,383
R01 · FY2004 · CA
Novel Lipid Signaling Pathways in Ovarian Cancer Cells$340,425
R01 · FY2003 · CA
Novel Bioactive Lipid Receptors in Growth Regulation$296,370
R01 · FY2003 · CA
Novel Bioactive Lipid Receptors in Growth Regulation$290,090
R01 · FY2002 · CA
NEW METHOD FOR THE EARLY DETECTION OF OVARIAN CANCER$111,000
R21 · FY2001 · CA
NEW METHOD FOR THE EARLY DETECTION OF OVARIAN CANCER$111,000
R21 · FY2000 · CA